Government of Principality of Monaco supports GARDP’s efforts to tackle drug-resistant sepsis in newborns

[Geneva – 23 May 2019] 

[French]

The Global Antibiotic Research and Development Partnership (GARDP) is pleased to announce funding of €400,000 from the Government of the Principality of Monaco. This grant is being formalized at the 2019 World Health Assembly, where antimicrobial resistance (AMR) is a priority topic.

The funds will be used to support the GARDP’s programme to combat neonatal sepsis in South Africa, where antimicrobial resistance is a major issue.

Infectious diseases are the leading cause of death and disability in children. More than half of all deaths in children under 5 years-old are in neonates (newborns up to 28-days-old). Drug-resistant infections are responsible for an estimated 214,000 deaths from neonatal sepsis a year (1). The situation is further aggravated by the increase in antimicrobial resistance.

GARDP wishes to thank the Principality of the Government of Monaco for its support” said Dr Manica Balasegarem, Director of GARDP. “The funding contributes to an urgent public health need – efforts to develop antibiotics to treat sepsis in newborns. The clinical trial network in South Africa will also form part of a global children’s antibiotic platform.

Monegasque funding will enable the development of new antibiotic treatments and a scientific database for the effective use of antibiotics to improve the medical care of newborns and children.

Monaco is delighted to be part of the group of countries supporting this GARDP initiative,” said Bénédicte Schutz, Director of International Cooperation of the Government of Monaco. The reduction of infant mortality, which is the matter here, remains a priority area of intervention for the Principality’s official development assistance, and we are pleased that South Africa, a partner country of the Monegasque Cooperation, is at the heart of this initiative.

(1): Laxminaryian R, et al. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016 Jan 9;387(10014):168-75. doi: 10.1016/S0140-6736(15)00474-2. Epub 2015 Nov 18.

Notes :

About GARDP

GARDP is a not-for-profit research and development organization that addresses global public health needs by developing new or improved antibiotic treatments, while endeavouring to ensure their sustainable access. Initiated by the World Health Organization (WHO) and the Drugs for Neglected Disease initiative, GARDP is an important element of WHO’s Global Action Plan on Antimicrobial Resistance that calls for new public-private partnerships to encourage research and development of new antimicrobial agents and diagnostics. 

About the Government of the Principality of Monaco

The Government of the Principality’s international development policy, which prioritizes combatting poverty, supports more than 130 projects each year in 11 countries, primarily Least Developed Countries (Madagascar, Mali, Burkina Faso, Niger, Mauritania, Senegal and Burundi). It focuses on four key areas of intervention to develop human capital – health, education, socio-economic inclusion and since 2018 food security – and targets the most vulnerable people (women, children, refugees, people with disabilities) as a priority. https://cooperation-monaco.gouv.mc/en

 

Contacts :

GARDP :

Susan Frade (Senior Communications Manager) – sfrade@gardp.org – +41 79 640 0099

 

Direction de la Coopération Internationale du Gouvernement Princier :

Yordanos Pasquier (Projet) – ypasquier@gouv.mc – +377 98 98 48 39

Julien Siri (Presse) – jsiri@gouv.mc – +377 98 98 39 46